Ticagrelor S.K., co-administered with acetylsalicylic acid (ASA), is indicated for the prevention of atherothrombotic events in adult patients with – acute coronary syndromes (ACS) or- a history of myocardial infarction (MI) and a high risk of developing an atherothrombotic event.
Limitations of use: 90 mg twice daily during the first year after an ACS event followed by 60 mg twice daily for additional 2 years.
